Market Cap 12.50B
Revenue (ttm) 2.17B
Net Income (ttm) 521.27M
EPS (ttm) N/A
PE Ratio 19.82
Forward PE 17.83
Profit Margin 24.04%
Debt to Equity Ratio 0.00
Volume 1,079,600
Avg Vol 2,887,206
Day's Range N/A - N/A
Shares Out 268.11M
Stochastic %K 89%
Beta 0.40
Analysts Strong Sell
Price Target $45.70

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 837 7000
Fax: 650 837 8300
Address:
1851 Harbor Bay Parkway, Alameda, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 7:40 PM
$EXEL RSI: 60.74, MACD: 0.9764 Vol: 1.80, MA20: 43.33, MA50: 41.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Jblack500
Jblack500 Dec. 24 at 2:45 PM
@WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy @MaverikIT $ABVX $MRK $CRDF $BBIO $EXEL ELAN ALNY ABBV GILD biotech basket currently (and animal health)
1 · Reply
Jblack500
Jblack500 Dec. 24 at 4:36 AM
0 · Reply
Jblack500
Jblack500 Dec. 24 at 4:36 AM
$ABVX $BBIO $EXEL $MRK read this pair of posts after the set below these
0 · Reply
Jblack500
Jblack500 Dec. 24 at 4:32 AM
0 · Reply
Jblack500
Jblack500 Dec. 24 at 4:30 AM
$ABVX $BBIO $EXEL $MRK $ALNY I wanted to share this conversation I had on ABVX and how I get to my target price
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Dec. 24 at 3:16 AM
Sold incy from mid 60s today and averaged up on Nektar. Now just own these 3 in order: $EXEL $UTHR $NKTR
0 · Reply
Office21
Office21 Dec. 23 at 2:52 PM
$EXEL sold all shares for a 24% gain
0 · Reply
Jblack500
Jblack500 Dec. 22 at 4:02 PM
@WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy @MaverikIT $CRDF $ABVX $EXEL $BBIO $MRK ELAN GILD ..crdf moving up 10%...reposted because I had the wrong mav on dec 19
1 · Reply
OtherOtttawaGuy
OtherOtttawaGuy Dec. 22 at 2:23 PM
$EXEL Where do we close out the year? Can we see a 52 wk high?
0 · Reply
Latest News on EXEL
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:06 PM EST - 7 weeks ago

Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript


Exelixis Announces Appointment of Dana T. Aftab, Ph.D.

Aug 29, 2025, 5:47 PM EDT - 4 months ago

Exelixis Announces Appointment of Dana T. Aftab, Ph.D.


Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 10:51 PM EDT - 5 months ago

Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript


Product Performance, Big Money Lift Exelixis

May 23, 2025, 6:25 AM EDT - 7 months ago

Product Performance, Big Money Lift Exelixis


Exelixis: A Notable Quarter

May 14, 2025, 2:53 PM EDT - 8 months ago

Exelixis: A Notable Quarter


Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

May 13, 2025, 8:31 PM EDT - 8 months ago

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript


EXEL Industries: Second quarter 2024–2025 sales down 3.8%

Apr 29, 2025, 2:02 AM EDT - 8 months ago

EXEL Industries: Second quarter 2024–2025 sales down 3.8%


Exelixis Growth Continues with Big Money Boosts

Mar 19, 2025, 7:09 AM EDT - 10 months ago

Exelixis Growth Continues with Big Money Boosts


Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Feb 21, 2025, 1:30 PM EST - 10 months ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?


OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 7:40 PM
$EXEL RSI: 60.74, MACD: 0.9764 Vol: 1.80, MA20: 43.33, MA50: 41.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Jblack500
Jblack500 Dec. 24 at 2:45 PM
@WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy @MaverikIT $ABVX $MRK $CRDF $BBIO $EXEL ELAN ALNY ABBV GILD biotech basket currently (and animal health)
1 · Reply
Jblack500
Jblack500 Dec. 24 at 4:36 AM
0 · Reply
Jblack500
Jblack500 Dec. 24 at 4:36 AM
$ABVX $BBIO $EXEL $MRK read this pair of posts after the set below these
0 · Reply
Jblack500
Jblack500 Dec. 24 at 4:32 AM
0 · Reply
Jblack500
Jblack500 Dec. 24 at 4:30 AM
$ABVX $BBIO $EXEL $MRK $ALNY I wanted to share this conversation I had on ABVX and how I get to my target price
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Dec. 24 at 3:16 AM
Sold incy from mid 60s today and averaged up on Nektar. Now just own these 3 in order: $EXEL $UTHR $NKTR
0 · Reply
Office21
Office21 Dec. 23 at 2:52 PM
$EXEL sold all shares for a 24% gain
0 · Reply
Jblack500
Jblack500 Dec. 22 at 4:02 PM
@WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy @MaverikIT $CRDF $ABVX $EXEL $BBIO $MRK ELAN GILD ..crdf moving up 10%...reposted because I had the wrong mav on dec 19
1 · Reply
OtherOtttawaGuy
OtherOtttawaGuy Dec. 22 at 2:23 PM
$EXEL Where do we close out the year? Can we see a 52 wk high?
0 · Reply
Jblack500
Jblack500 Dec. 22 at 1:24 PM
$ABVX $EXEL $BBIO I expect abivax to fetch minimum 14bil on a buyout. Merck bought prometheus for 10.6 bill at 200 dollars a share a little over 2 years ago and that mainly was for p2 ibd asset. Obituary, abvx is much further along at this juncture...it would be my 5th buyout..being in previously celgene,array, Seattle genetics, and pharmacyclics. EXEL if zanza goes well is a good possibility as well in oncology
2 · Reply
Jblack500
Jblack500 Dec. 22 at 1:02 PM
@WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy @MaverikIT $ABVX $EXEL $BBIO wanted to resend this because I forgot mav on here Friday
1 · Reply
Jblack500
Jblack500 Dec. 19 at 11:56 PM
@cynicaloptimist @FannyPackin @WAJeff @Thelonius_Stonk @osubuckeye @Clargy $ALNY $BBIO $ABVX $MRK $EXEL GILD ...initiated a position in alny..that's me at 401...I like the support at 390...
1 · Reply
Jblack500
Jblack500 Dec. 19 at 8:46 PM
@cynicaloptimist @FannyPackin @WAJeff @Thelonius_Stonk @osubuckeye @Clargy $ABVX $EXEL $BBIO aside from abivax as a top biotech buyout in 2026 I also see Exelixis being acquired (I'm thinking the buyer would be Merck) contingent on successful of trials for their Zanza drug. Big pharma is losing some huge oncology assets due to patent cliffs and they desperately need to replenish their pipelines. Exel has solid revenue , a low p/e, and their key next generation asset (Zanza) currently in ongoing studies. On 11/26 a director purchased 1.2 mil in common stock. R&d day was a week ago...citizens reiterated a buy post r&d...I see acquisition being north of 16bil cap if zanza proves successful. Under the radar but it shouldn't be. Slightly tricky entry here on the chart. Entry here would probably work better on a clean move to new 52 week highs or on a no news pullback
3 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:19 PM
Actionable Trade Alert for $EXEL: Market Context: $EXEL is currently trading at $42.57. The RSI of 39.33 indicates that the stock is nearing oversold territory, suggesting potential upward momentum. The price is above the 30-day moving average (MA30) of $42.45 but below the 50-day moving average (MA50) of $40.87, indicating a bullish bias in the short term. Directional Bias: Given the current RSI and the proximity to the 60-day high of $44.91, there is potential for a rebound. The recent low of $33.76 provides a solid support level. Trade Plan: - Suggested Entry: $42.57 - Stop Loss: $40.00 (approximately 6% below entry) - Take Profit Targets: 1. $44.00 (5.5% gain) 2. $45.50 (6.7% gain) 3. $50.00 (17.5% gain) This plan offers a risk-reward ratio that aligns with our goal of achieving at least a 17% ROI on the third target. Monitor closely for volatility with an ATR of 1.11. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:06 AM
Actionable Trade Alert for $EXEL: Market Context: $EXEL is currently trading at $41.6, showing a bearish sentiment with an RSI of 40.0, indicating potential oversold conditions. The stock is below both the 30-day MA of 42.24 and the 50-day MA of 40.74, suggesting a downward trend. However, the price is above the 60-day low of 33.76, indicating possible support. Directional Bias: The RSI suggests a potential reversal, and with the price near the lower end of the 60-day range, there is a chance for a rebound. Trade Plan: - Suggested Entry: $41.6 - Stop Loss: $39.5 (approximately 5% below entry) - Take Profit Targets: 1. $43.0 (3.4% gain) 2. $44.0 (5.7% gain) 3. $48.5 (16.5% gain) With the potential for a 17% ROI or more on the third target, this trade offers a favorable risk-reward ratio. Monitor closely for market changes. https://privateprofiteers.com
0 · Reply
juice_rock
juice_rock Dec. 16 at 8:14 PM
$EXEL undervalued oncology
0 · Reply
Invest2live
Invest2live Dec. 16 at 3:46 AM
$DLTR 20% already; congrats 🎊 🎉🎈 Checkout $HRMY and $EXEL; undervalued with 50+ percent potential
0 · Reply
Invest2live
Invest2live Dec. 15 at 4:31 PM
$EXEL don’t lose your cheap shares. This has a long way to go. Slow and study :-)
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:39 AM
Actionable Trade Alert for $EXEL: Market Context: $EXEL is currently trading at $40.88, with an RSI of 39.9 indicating it is in the oversold territory, suggesting potential for a rebound. The stock is below its 30-day moving average (MA30) of $42.03 and 50-day moving average (MA50) of $40.69, indicating bearish sentiment. However, the 60-day high of $44.91 and low of $33.76 provide a range for potential price movement. Directional Bias: Given the current RSI and proximity to the 60-day low, we anticipate a bullish reversal in the near term. Trade Plan: - Suggested Entry: $40.90 - Stop Loss: $38.50 (approx. 5.9% below entry) - Take Profit Targets: 1. $42.00 (2.7% ROI) 2. $43.00 (5.4% ROI) 3. $48.00 (17.5% ROI) With the potential for a significant upside, this trade offers a favorable risk-reward ratio. Execute this plan with caution and monitor market conditions closely. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:33 PM
Actionable Trade Alert for $EXEL: Market Context: $EXEL is currently trading at $41.68, with a neutral RSI of 49.42 indicating no immediate overbought or oversold conditions. The stock is positioned between its 60D high of $44.91 and low of $33.76, suggesting potential for upward movement. Directional Bias: The 30-day moving average (MA30) at $41.97 is slightly above the current price, indicating resistance. However, the 50-day moving average (MA50) at $40.70 provides support. This setup suggests a bullish bias if the price breaks above the MA30. Trade Plan: - Suggested Entry: $42.00 (break above MA30) - Stop Loss: $39.50 (below MA50) - Take Profit Targets: 1. $43.00 (2.38% gain) 2. $44.00 (4.76% gain) 3. $48.00 (15.83% gain) With a potential 15.83% ROI at target 3, this trade presents a favorable risk-reward scenario. Monitor closely for price action around key levels. https://privateprofiteers.com
0 · Reply
OtherOtttawaGuy
OtherOtttawaGuy Dec. 11 at 2:59 PM
$EXEL Any idea where this is going, Fib retrace or otherwise?
0 · Reply